Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)
2022 · Annals of Oncology · 87 citations
https://doi.org/10.1016/j.annonc.2022.02.225
M
Melanie Janning
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
92
Papers
2.0K
Citations
22
h-index
37
i10-index
Melanie Janning is an academic researcher from German Cancer Research Center. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Genomics and Diagnostics & Phagocytosis and Immune Regulation. The author has an h-index of 22, co-authored 79 publications.
ORCID: 0000-0002-6632-8506Papers by this author
worksQuantitative Chemical Proteomics Reveals New Potential Drug Targets in Head and Neck Cancer
2011 · Molecular & Cellular Proteomics · 77 citations
https://doi.org/10.1074/mcp.m111.011635
Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B
2017 · Nature Communications · 74 citations
https://doi.org/10.1038/s41467-017-00327-8
Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy
2022 · Annals of Hematology · 7 citations
https://doi.org/10.1007/s00277-022-05075-4
Profile of the multicenter cohort of the German Cancer Consortium’s Clinical Communication Platform
2023 · European Journal of Epidemiology · 6 citations
https://doi.org/10.1007/s10654-023-00990-w
Treatment outcome of NSCLC patients with BRAF mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany
2025 · ESMO Open · 3 citations
https://doi.org/10.1016/j.esmoop.2025.105124
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat